Biomarin Pharmaceutical Inc (BMRN)
90.45
+0.37
(+0.41%)
USD |
NASDAQ |
Apr 19, 09:34
Biomarin Pharmaceutical Revenue (TTM): 2.419B for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.419B |
| September 30, 2023 | 2.311B |
| June 30, 2023 | 2.235B |
| March 31, 2023 | 2.173B |
| December 31, 2022 | 2.096B |
| September 30, 2022 | 2.008B |
| June 30, 2022 | 1.912B |
| March 31, 2022 | 1.880B |
| December 31, 2021 | 1.846B |
| September 30, 2021 | 1.849B |
| June 30, 2021 | 1.917B |
| March 31, 2021 | 1.844B |
| December 31, 2020 | 1.860B |
| September 30, 2020 | 1.863B |
| June 30, 2020 | 1.847B |
| March 31, 2020 | 1.805B |
| December 31, 2019 | 1.704B |
| September 30, 2019 | 1.603B |
| June 30, 2019 | 1.533B |
| March 31, 2019 | 1.519B |
| December 31, 2018 | 1.491B |
| September 30, 2018 | 1.496B |
| June 30, 2018 | 1.439B |
| March 31, 2018 | 1.383B |
| December 31, 2017 | 1.314B |
| Date | Value |
|---|---|
| September 30, 2017 | 1.255B |
| June 30, 2017 | 1.201B |
| March 31, 2017 | 1.184B |
| December 31, 2016 | 1.117B |
| September 30, 2016 | 1.045B |
| June 30, 2016 | 973.71M |
| March 31, 2016 | 923.71M |
| December 31, 2015 | 889.90M |
| September 30, 2015 | 892.03M |
| June 30, 2015 | 859.67M |
| March 31, 2015 | 801.32M |
| December 31, 2014 | 749.96M |
| September 30, 2014 | 666.76M |
| June 30, 2014 | 627.09M |
| March 31, 2014 | 572.11M |
| December 31, 2013 | 548.48M |
| September 30, 2013 | 533.55M |
| June 30, 2013 | 524.79M |
| March 31, 2013 | 512.00M |
| December 31, 2012 | 500.72M |
| September 30, 2012 | 476.63M |
| June 30, 2012 | 461.94M |
| March 31, 2012 | 448.55M |
| December 31, 2011 | 441.36M |
| September 30, 2011 | 435.13M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
1.533B
Minimum
Jun 2019
2.419B
Maximum
Dec 2023
1.932B
Average
1.863B
Median
Sep 2020
Revenue (TTM) Benchmarks
| Eli Lilly and Co | 34.12B |
| Pfizer Inc | 58.50B |
| Regeneron Pharmaceuticals Inc | 13.12B |
| Vertex Pharmaceuticals Inc | 9.869B |
| Moderna Inc | 6.754B |